



LETTER TO THE EDITOR

Sprue-Like Enteropathy Associated with Olmesartan: An Unrecognized Emerging Drug-Induced Enteropathy?



Enteropatia *Sprue-Like* Associada com o Olmesartan: Uma Enteropatia Induzida por Fármaco Emergente e Sub-Diagnosticada?

Dear Editors,

We read with great interest the case reports by da Silva *et al.*¹, Carneiro *et al.*² and Eusébio *et al.*³ published in the late issue of *GE Portuguese Journal of Gastroenterology*.

We would like to emphasize the clinical relevance of this topic regarding its, until recently, unrecognized features and share our small case-series experience (Table 1).

Curiously, in both cases symptoms developed long (fourteen and ten months, respectively) after starting therapy. This has rarely been addressed and may difficult the diagnosis.

The primary care physicians were informed and advised to switch class of medication in these cases. There were no recurrences of symptoms during follow-up.

Table 1 Clinical features of two cases of sprue-like enteropathy associated with olmesartan. F, Female; hypoK, hipokalemia; hypoAlb, hypoalbuminemia; hypoMg, hypomagnesemia.

| Sex | Age | Time of diagnosis | Clinical presentation | Duration of symptoms | Laboratorial findings | Response to eviction of olmesartan | Time of follow-up endoscopy/histology | Resolution of histological changes |
|-----|-----|-------------------|--|----------------------|---|------------------------------------|---------------------------------------|------------------------------------|
| F | 72 | 2014 | Chronic diarrhea; abdominal discomfort | 6 months | Normocytic anemia; hypoK; hypoAlb | Clinical remission | 3 months | Yes |
| F | 52 | 2015 | Chronic diarrhea | 4 months | Electrolyte abnormalities (severe hypoK and hypoMg) | Clinical remission | 6 months | Yes |

DOIs of original articles:

<http://dx.doi.org/10.1016/j.jpge.2015.10.007>,
<http://dx.doi.org/10.1016/j.jpge.2015.12.003>,
<http://dx.doi.org/10.1016/j.jpge.2015.09.005>

<http://dx.doi.org/10.1016/j.jpge.2016.06.004>

2341-4545/© 2016 Sociedade Portuguesa de Gastreenterologia. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

References

1. da Silva BM, Neves SJ, Martínez AG, de Jesus Geneux K, García JL, Antolín SM, et al. Enteropathy associated with olmesartan. *GE Port J Gastroenterol.* 2016;23:96–100.
2. Carneiro L, Moreira A, Pereira A, Andrade A, Soares J, Silva A, et al. Olmesartan-induced sprue like enteropathy. *GE Port J Gastroenterol.* 2016;23:101–5.
3. Eusébio M, Caldeira P, Gão Antunes A, Ramos A, Velasco F, Cadillá J, et al. Olmesartan-induced enteropathy – an unusual cause of villous atrophy. *GE Port J Gastroenterol.* 2016;23:91–5.

Luís Carvalho Lourenço*, Joana Carvalho e Branco, Liliana Santos, Alexandra Martins, Jorge Reis

Gastroenterology Department, Hospital Prof. Doutor Fernando Fonseca, Amadora, Portugal

* Corresponding author.

E-mail address: luisclourenco@gmail.com (L.C. Lourenço).